These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 28673045

  • 1. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3452-3460. PubMed ID: 28673045
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul 01; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 3. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.
    J Clin Lipidol; 2015 Jul 01; 9(5):664-75. PubMed ID: 26350813
    [Abstract] [Full Text] [Related]

  • 4. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar 01; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 5. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.
    Circulation; 2017 Jan 24; 135(4):352-362. PubMed ID: 27986651
    [Abstract] [Full Text] [Related]

  • 6. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Jan 24; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 7. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.
    Circulation; 2014 Jul 29; 130(5):431-41. PubMed ID: 25070550
    [Abstract] [Full Text] [Related]

  • 8. The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
    Gagnon A, Ooi TC, Cousins M, Favreau C, Henry K, Landry A, Sorisky A.
    Obesity (Silver Spring); 2016 Nov 29; 24(11):2384-2391. PubMed ID: 27662822
    [Abstract] [Full Text] [Related]

  • 9. Protective lipid-lowering variants in healthy older individuals without coronary heart disease.
    Lacaze P, Riaz M, Sebra R, Hooper AJ, Pang J, Tiller J, Polekhina G, Tonkin A, Reid C, Zoungas S, Murray AM, Nicholls S, Watts G, Schadt E, McNeil JJ.
    Open Heart; 2021 Jul 29; 8(2):. PubMed ID: 34341098
    [Abstract] [Full Text] [Related]

  • 10. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W, Le May C, Cariou B.
    Trends Endocrinol Metab; 2018 Jun 29; 29(6):420-434. PubMed ID: 29665987
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN, Krempf M, Bruckert E, Donahue S, Yang F, Zhang Y, DiCioccio AT.
    J Clin Lipidol; 2019 Jun 29; 13(6):970-978. PubMed ID: 31767518
    [Abstract] [Full Text] [Related]

  • 12. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.
    Arterioscler Thromb Vasc Biol; 2012 Jul 29; 32(7):1585-95. PubMed ID: 22580899
    [Abstract] [Full Text] [Related]

  • 13. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
    Guan Y, Hou X, Tian P, Ren L, Tang Y, Song A, Zhao J, Gao L, Song G.
    Front Endocrinol (Lausanne); 2021 Jul 29; 12():646185. PubMed ID: 33967959
    [Abstract] [Full Text] [Related]

  • 14. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG, Dufour R, Davignon J, Baass A.
    Arterioscler Thromb Vasc Biol; 2014 Dec 29; 34(12):2700-5. PubMed ID: 25278291
    [Abstract] [Full Text] [Related]

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.
    Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J, PREVENT-AD Research Group.
    PLoS One; 2019 Dec 29; 14(8):e0220254. PubMed ID: 31437157
    [Abstract] [Full Text] [Related]

  • 16. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR.
    J Clin Endocrinol Metab; 2016 Sep 29; 101(9):3281-7. PubMed ID: 27218270
    [Abstract] [Full Text] [Related]

  • 17. The characteristics of remnant lipoproteins in the fasting and postprandial plasma.
    Nakajima K, Nakano T, Tokita Y, Nagamine T, Yatsuzuka S, Shimomura Y, Tanaka A, Sumino H, Nara M, Machida T, Murakami M.
    Clin Chim Acta; 2012 Jul 11; 413(13-14):1077-86. PubMed ID: 22433787
    [Abstract] [Full Text] [Related]

  • 18. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun 11; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 19. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome.
    Vine DF, Wang Y, Jetha MM, Ball GD, Proctor SD.
    J Clin Endocrinol Metab; 2017 Mar 01; 102(3):970-982. PubMed ID: 27997268
    [Abstract] [Full Text] [Related]

  • 20. Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.
    Lee CJ, Lee Y, Park S, Kang SM, Jang Y, Lee JH, Lee SH.
    PLoS One; 2017 Mar 01; 12(10):e0186446. PubMed ID: 29036232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.